Zachary Wallace to Antirheumatic Agents
This is a "connection" page, showing publications Zachary Wallace has written about Antirheumatic Agents.
Connection Strength
0.950
-
COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021 05 01; 33(3):255-261.
Score: 0.308
-
COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep. 2021 04 24; 23(5):28.
Score: 0.307
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.077
-
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol. 2021 01; 73(1):36-47.
Score: 0.075
-
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 10; 50(5):1191-1201.
Score: 0.073
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.072
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.019
-
SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis. 2021 02; 80(2):269-271.
Score: 0.018